Liver Disease: Clinical Trials

123 trials for Liver Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

73 completed, 21 unknown, 13 terminated, 6 withdrawn. 31 Not applicable, 19 Phase 1, 15 Phase 4, 14 Phase 2, 8 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable31Completed 15, Terminated 6, Unknown 6, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1
Phase 119Completed 12, Unknown 3, Terminated 2, Withdrawn 2
Phase 415Completed 9, Terminated 3, Unknown 2, Withdrawn 1
Phase 214Completed 7, Withdrawn 3, Terminated 2, Unknown 2
Phase 38Completed 5, Unknown 2, Terminated 1
Early Phase 11Completed 1

Follow Liver Disease: new trials by email Literature Review of Liver Disease trials Research Report on Liver Disease

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
Behavioral Treatment - Type 2 Diabetes, Liver Disease
Not applicableNot yet recruitingSIPPA Solutions INC1802026-08-202026-09-14
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
No treatment is given - Liver Disease
RecruitingNovo Nordisk A/S4702026-06-032026-07-02
Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices
Blood samples are obtained and pseudonymized, prior to use for the development, optimization and calibration of diagnostic tests - Blood Clots, Infection and Inflammatory Reaction
Not yet recruitingLumiraDx UK Limited300002026-04-012026-01-30
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Efinopegdutide - Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Phase 2CompletedMerck Sharp & Dohme LLC1242024-07-292026-06-01
Online Prehabilitation for Patients Awaiting Liver Transplantation
Prehabilitation Programming - Cirrhosis, Liver, Liver Transplant Surgery
Not applicableActive not recruitingUniversity of Alberta1792023-07-122026-11-04
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
COVID-19, Liver Disease
CompletedHepatopancreatobiliary Surgery Institute of Gansu Province10002021-05-112023-04-25
The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.
triopifexor, Placebo - Liver Disease
Phase 1CompletedNovartis Pharmaceuticals892020-05-292022-02-09
Safety and Efficacy of Fecal Microbiota Transplantation
Fecal Microbiota Transplantation - Crohn Disease, Ulcerative Colitis
Not applicableRecruitingChinese University of Hong Kong4502019-07-152024-08-22
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Azacitidine, Pevonedistat - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 1CompletedTakeda172019-07-102024-09-05
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Elafibranor - Hepatic Impairment, Liver Disease
Phase 1CompletedGenfit302018-12-122019-08-22
Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese
Jarlsberg cheese - Heathy Women, Pre Menopausal Age
Not applicableCompletedProf Stig Larsen202018-09-012023-01-11
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)262018-08-012021-12-14
Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study
Caffeine citrate - Liver Disease
Phase 1WithdrawnUniversity of Birmingham2018-03-012018-04-19
deLIVER: Direct Acting Antiviral Effects on the Liver
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL) - HCV Coinfection, Liver Disease
Phase 4CompletedJohns Hopkins University152017-01-012022-02-24
Controlled Attenuation Parameter (CAP) in Liver Allografts
Fibroscan 402/530 - Liver Transplant, Liver Steatosis
CompletedAndres Duarte-Rojo1602016-09-072020-07-31
Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
Enteral fish oil, Ursodeoxycholic Acid, Placebo - Cholestasis, Liver Disease
Phase 2WithdrawnThe University of Texas Health Science Center at San Antonio2016-06-012016-06-21
Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)
HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate), Hepatic Venous Pressure Gradient (HVPG) - Liver Disease
Phase 3CompletedUniversity of Colorado, Denver202016-03-012021-08-09
Effect of Synbiotic on Postoperative Complications After Liver Transplantation
Synbiotic, Control - Liver Disease
Not applicableUnknownHospital de Clinicas de Porto Alegre762016-03-012016-10-19
Minocycline Administration During Human Liver Transplantation
Minocycline (yes/no), Placebo - Liver Disease
Phase 4WithdrawnMedical University of South Carolina2016-03-012018-06-18
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
sofosbuvir/ledipasvir, sofosbuvir, Ribavirin - Liver Disease
Phase 4TerminatedUniversity of Texas Southwestern Medical Center12016-02-252019-01-08

Showing 20 of 123. Sign in to see all of them.

Narrower conditions

Liver Diseases (123)  ·  Hepatitis C (10)  ·  Fibrosis (8)  ·  Kidney Diseases (7)  ·  Non-alcoholic Fatty Liver Disease (7)  ·  Liver Cirrhosis (6)  ·  Cholestasis (5)  ·  Alcoholism (4)  ·  Carcinoma, Hepatocellular (4)  ·  Fatty Liver (4)  ·  Hepatitis B (4)  ·  Diabetes Mellitus (3)  ·  Heart Diseases (3)  ·  Heart Failure (3)  ·  Hepatitis C, Chronic (3)

Broader conditions

Digestive System Diseases (121)  ·  Pathological Conditions, Signs and Symptoms (39)  ·  Pathologic Processes (31)  ·  Infections (20)  ·  Virus Diseases (16)  ·  RNA Virus Infections (14)  ·  Blood-Borne Infections (13)  ·  Communicable Diseases (13)  ·  Hepatitis, Viral, Human (13)  ·  Hepatitis (12)  ·  Signs and Symptoms (12)  ·  Flaviviridae Infections (11)  ·  Nutritional and Metabolic Diseases (10)  ·  Urogenital Diseases (10)  ·  Female Urogenital Diseases (9)

Interventions

Ribavirin (4)  ·  Tacrolimus (4)  ·  Hepatectomy (3)  ·  Blood Specimen Collection (2)  ·  Mycophenolic Acid (2)  ·  Propofol (2)  ·  Sofosbuvir (2)  ·  Ursodeoxycholic Acid (2)  ·  alisporivir (2)  ·  conivaptan (2)  ·  fish oil triglycerides (2)  ·  2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1)  ·  4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid (1)  ·  Alemtuzumab (1)  ·  Anesthesia, Conduction (1)

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8)  ·  Federal University of Minas Gerais (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  National Taiwan University Hospital (3)  ·  Cumberland Pharmaceuticals (2)  ·  Debiopharm International SA (2)  ·  Helse Nord-Trøndelag HF (2)  ·  Johns Hopkins Bloomberg School of Public Health (2)  ·  Maastricht University Medical Center (2)  ·  Medical University of South Carolina (2)  ·  Rutgers, The State University of New Jersey (2)  ·  Samsung Medical Center (2)  ·  The University of Texas Health Science Center at San Antonio (2)  ·  University of California, San Francisco (2)  ·  University of Chicago (2)

Countries

United States (62)  ·  United Kingdom (7)  ·  Brazil (5)  ·  France (5)  ·  China (4)  ·  Germany (4)  ·  Belgium (3)  ·  Canada (3)  ·  Israel (3)  ·  Netherlands (3)  ·  Norway (3)  ·  South Korea (3)  ·  Switzerland (3)  ·  Taiwan (3)  ·  Italy (2)

Top investigators

Art Wheeler, MD (2)  ·  Baburao Koneru, M.D. (2)  ·  Yaron Rotman, M.D. (2)  ·  Aldo Torre Delgadillo, M.D., M. Sc. (1)  ·  Alessandra Mangia, MD (1)  ·  Amanda Wieland, MD (1)  ·  Amy Pollack, MD (1)  ·  Andres Duarte-Rojo, MD (1)  ·  Antonio Daniele Pinna, MD (1)  ·  Asuncion Moreno, MD (1)  ·  Babuaro Koneru, MD (1)

Results publications

PMID 12149596, PMID 15888204, PMID 16003227, PMID 16029225, PMID 16539632, PMID 16628690, PMID 16850377, PMID 16970840, PMID 17058231, PMID 17195325, PMID 17611251, PMID 17635375, PMID 17876267, PMID 17949458, PMID 17949460, PMID 18031464, PMID 19059920, PMID 19268724, PMID 19281442, PMID 19298451, PMID 19776780, PMID 19800334, PMID 19940946, PMID 20005373, PMID 20346065, PMID 20921898, PMID 21083386, PMID 21092252, PMID 21535051, PMID 21680855, PMID 21810825, PMID 22030902, PMID 22410036, PMID 22510354, PMID 22521347, PMID 22559239, PMID 22563020, PMID 22647561, PMID 22759736, PMID 22762561, PMID 22858882, PMID 22938898, PMID 23290631, PMID 23492964, PMID 23512786, PMID 23625132, PMID 23714349, PMID 23739141, PMID 23828202, PMID 24030928

NIH funding

U01DK061730 (2), 2008 (1), 2018 (1), R01DK058763 (1), R01DK066368 (1), R03DK055618 (1), U01AI052748 (1), UL1TR001082 (1)